Tiziana Life Sciences Ltd.: Tiziana Enrolls Second Patient i

- Clinical data from the first patient, after completing 3 out of 6 months, suggest that the treatment was well tolerated with a favorable clinical response - FDA allows for continued enrollment under

Related Keywords

Boston , Massachusetts , United States , United Kingdom , Harvard University , Kunwar Shailubhai , Irina Koffler , Howard Weiner , Gabriele Cerrone , Tanuja Chitnis , Lifesci Advisors , Drug Administration , Tiziana Life Sciences , Professor Of Neurology At Harvard Medical School , Tiziana Life Sciences Nasdaq , Patient Expanded Access Program , Sclerosis Program , Individual Patient Expanded Access , Life Sciences , Chief Executive Officer , Positron Emission Tomography , Expanded Disability Status Scale , Multiple Sclerosis Program , Scientific Advisory Board , Principal Investigator , Harvard Medical School , Massachusetts General Hospital , Sci Advisors , Tiziana , Life , Ciences , Enrolls , Second , Patient , Ngoing , Intranasal , Foralumab , Evaluation , Secondary , Progressive , Multiple , Clerosis ,